Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has received a Demand Notice from the National Pharmaceutical Pricing Authority for manufacturing and marketing a new drug/formulation without obtaining prior price approval, resulting in a demand of Rs. 52,74,68,193/- including overcharging amount of Rs. 18,94,80,649/- and penalty amount of Rs. 18,94,80,649/- along with interest amount of Rs. 14,85,06,895/-.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd received a certificate from MUFG Intime India Private Limited confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September, 2026.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has announced the closure of its trading window for all designated persons, including their immediate relatives, from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ending September 30, 2026.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has announced the schedule of institutional investors meets, to be held on September 28th and 29th, 2026. The meets will be held in Mumbai, and no unpublished price sensitive information will be shared during the meets.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has announced an investors/analysts meet on September 22, 2026, at Taj, Santacruz, Mumbai, as part of the G200 Summit 2026. No unpublished price sensitive information will be shared during the meet.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has received an ESG rating of '65' for FY 2025-26 from NSE Sustainability Ratings & Analytics Limited, a subsidiary of NSE Indices Limited.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has informed about its participation in an investor/analysts meet on 2nd September 2026 at Hyatt, Santacruz, Mumbai. The meet is part of the India Dialogue 2026 and will start at 02:00 PM (IST). No unpublished price sensitive information will be shared during the meet.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has cancelled its participation in an Investors/Analysts Meet on August 25, 2026, due to medical reasons.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has announced an investor/analysts meet on August 25, 2026, at Trident, BKC, Mumbai, starting at 09:00 AM IST. No unpublished price-sensitive information will be shared during the meet.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has announced its unaudited financial results for Q1 FY 27, with a revenue growth of over 13% and EBITDA increasing by more than 30%. The company has also acquired Oriflame India's manufacturing business, expanding its manufacturing footprint in skin care cosmetics and wellness products.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has announced an investor/analysts meet on August 14, 2026, at Grand Hyatt, India. The meet is part of Regulation 30 under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. No unpublished price-sensitive information will be shared during the meet.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd announces the link of audio recording of Investors/Analysts Conference Call for the un-audited financial results for the quarter ended June 30, 2026.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has published un-audited financial results for the quarter ended June 30, 2026, as approved by the Board of Directors on August 08, 2026.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, detailing the utilization of proceeds from its Initial Public Offer (IPO). The report, issued by CRISIL Ratings Limited, Monitoring Agency, indicates that the company has not deviated from the objects of the issue and has utilized the net proceeds of Rs 6,421.80 million for the intended purposes.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd announced its Q1 FY27 results, registering a 13% revenue growth and a 30% increase in EBITDA. The company's CDMO segment saw double-digit volume growth, and the API segment improved its gross margins due to higher non-cepha product sales. The company also announced the acquisition of Oriflame India's manufacturing business for Rs 56 Crore.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd reported Q1 FY27 financial results with 13.9% YoY revenue growth, 35.4% YoY EBITDA growth, and 55.4% YoY PAT growth.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, with the Board of Directors considering and approving the results along with the Limited Review Reports from the Statutory Auditors, Walker Chandiok & Co LLP, Chartered Accountants. The results are enclosed as Annexure-A, and a Statement of Deviation pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended June 30, 2026, is enclosed as Annexure-B.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, with the Board of Directors considering and approving the results along with the Limited Review Reports from the Statutory Auditors. The company has also filed an appeal against a tax demand raised by the Income-tax authorities.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has scheduled a board meeting on 08/08/2026 to consider and approve the un-audited financial results for the quarter ended on 30th June, 2026. The trading window for trading in the securities of the Company will open after 48 hours of the declaration of the financial results.

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has announced the acquisition of Oriflame India's manufacturing business for INR 56 Crore. The acquisition includes two manufacturing plants and a leased warehouse, marking Akums' entry into the color cosmetics market and expanding its presence in skincare and wellness products.